<DOC>
	<DOCNO>NCT01574729</DOCNO>
	<brief_summary>The primary objective study investigate efficacy safety surgery combine rAd-p53 gene therapy treatment advance Non-small-cell lung carcinoma ( NSCLC ) . The study efficacy endpoint include overall survival , progress-free survival , quality life , local recurrent rate . The safety endpoint complication adverse effect . The study hypothesis : rAd-p53 gene therapy prolong overall survival reduce local recurrent rate .</brief_summary>
	<brief_title>Surgery Combined With rAd-p53 Gene Treatment Advanced Non-small-cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Li-Fraumeni Syndrome</mesh_term>
	<criteria>historically diagnose advanced nonsmall lung cancer surgery indication age 18 year old great life expectancy great 12 week ECOG : 02 prior chemotherapy , radiotherapy 2 week Neutrophils≥1.5×10^9/L , platelet≥80×10^9/L , Hb≥≥80g/L , bilirubin≤1.5×2mg/dl , ALT AST≤2×institutional upper limit normal , Cr≤1.5×institutional upper limit normal , coagulation test ( INR PTT ) within normal range subject provide sign informed consent hypersensitive study drug coagulational test unnormal bleeding disorder infection serious condition ca n't stand surgery pregnant lactate principle investigator consider suitable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>p53 gene therapy</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>post-surgery</keyword>
	<keyword>chemotherapy</keyword>
</DOC>